Your browser doesn't support javascript.
loading
Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis.
Li, Hong; Chiang, Chi-Ling; Kwak, Kwang Joo; Wang, Xinyu; Doddi, Sital; Ramanathan, Lakshmi V; Cho, Sun M; Hou, Ya-Chin; Cheng, Tai-Shan; Mo, Xiaokui; Chang, Yueh-Shih; Chang, Hui-Lan; Cheng, Weiming; Tsai, Wei-Ni; Nguyen, Luong T H; Pan, Junjie; Ma, Yifan; Rima, Xilal Y; Zhang, Jingjing; Reategui, Eduardo; Chu, Yeh-Shiu; Chang, Peter Mu-Hsin; Chang, Pei-Hung; Huang, Chi-Ying F; Wang, Cheng-Hsu; Shan, Yan-Shen; Li, Chung-Pin; Fleisher, Martin; Lee, L James.
Afiliação
  • Li H; Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH, 43210, USA.
  • Chiang CL; Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH, 43210, USA.
  • Kwak KJ; Spot Biosystems Ltd., Columbus, OH, 43212, USA.
  • Wang X; Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH, 43210, USA.
  • Doddi S; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Ramanathan LV; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Cho SM; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
  • Hou YC; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.
  • Cheng TS; Division of General Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.
  • Mo X; Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan.
  • Chang YS; Center for Biostatistics, Ohio State University, Columbus, OH, 43210, USA.
  • Chang HL; School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan.
  • Cheng W; Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, 20401, Taiwan.
  • Tsai WN; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan.
  • Nguyen LTH; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, 11217, Taiwan.
  • Pan J; Therapeutic and Research Center of Pancreatic Cancer, Taipei Veterans General Hospital, Taipei, 11217, Taiwan.
  • Ma Y; Division of Clinical Skills Training, Department of Medical Education, Taipei Veterans General Hospital, Taipei, 11217, Taiwan.
  • Rima XY; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan.
  • Zhang J; Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan.
  • Reategui E; Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan.
  • Chu YS; Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH, 43210, USA.
  • Chang PM; Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH, 43210, USA.
  • Chang PH; Department of Biomedical Engineering, Ohio State University, Columbus, OH, 43210, USA.
  • Huang CF; Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH, 43210, USA.
  • Wang CH; Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH, 43210, USA.
  • Shan YS; Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH, 43210, USA.
  • Li CP; Brain Research Center, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan.
  • Fleisher M; Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan.
  • Lee LJ; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, 11221, Taiwan.
Adv Sci (Weinh) ; 11(11): e2306373, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38204202
ABSTRACT
Detecting pancreatic duct adenocarcinoma (PDAC) in its early stages and predicting late-stage patient prognosis undergoing chemotherapy is challenging. This work shows that the activation of specific oncogenes leads to elevated expression of mRNAs and their corresponding proteins in extracellular vesicles (EVs) circulating in blood. Utilizing an immune lipoplex nanoparticle (ILN) biochip assay, these findings demonstrate that glypican 1 (GPC1) mRNA expression in the exosomes-rich (Exo) EV subpopulation and GPC1 membrane protein (mProtein) expression in the microvesicles-rich (MV) EV subpopulation, particularly the tumor associated microvesicles (tMV), served as a viable biomarker for PDAC. A combined analysis effectively discriminated early-stage PDAC patients from benign pancreatic diseases and healthy donors in sizable clinical from multiple hospitals. Furthermore, among late-stage PDAC patients undergoing chemotherapy, lower GPC1 tMV-mProtein and Exo-mRNA expression before treatment correlated significantly with prolonged overall survival. These findings underscore the potential of vesicular GPC1 expression for early PDAC screenings and chemotherapy prognosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Vesículas Extracelulares Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Adv Sci (Weinh) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Vesículas Extracelulares Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Adv Sci (Weinh) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
...